- Home
- IMNN vs SNTI Comparison
IMNN vs SNTI Comparison
Compare IMNN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- SNTI
- Stock Information
- Founded
- IMNN 1982
- SNTI 2016
- Country
- IMNN United States
- SNTI United States
- Employees
- IMNN N/A
- SNTI N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- SNTI Health Care
- Exchange
- IMNN Nasdaq
- SNTI Nasdaq
- Market Cap
- IMNN 12.1M
- SNTI 39.6M
- IPO Year
- IMNN 1985
- SNTI N/A
- Fundamental
- Price
- IMNN $5.75
- SNTI $1.35
- Analyst Decision
- IMNN Buy
- SNTI Strong Buy
- Analyst Count
- IMNN 2
- SNTI 2
- Target Price
- IMNN $182.61
- SNTI $8.50
- AVG Volume (30 Days)
- IMNN 55.7K
- SNTI 124.8K
- Earning Date
- IMNN 11-06-2025
- SNTI 11-13-2025
- Dividend Yield
- IMNN N/A
- SNTI N/A
- EPS Growth
- IMNN N/A
- SNTI N/A
- EPS
- IMNN N/A
- SNTI N/A
- Revenue
- IMNN N/A
- SNTI N/A
- Revenue This Year
- IMNN N/A
- SNTI N/A
- Revenue Next Year
- IMNN N/A
- SNTI $150.00
- P/E Ratio
- IMNN N/A
- SNTI N/A
- Revenue Growth
- IMNN N/A
- SNTI N/A
- 52 Week Low
- IMNN $4.83
- SNTI $1.26
- 52 Week High
- IMNN $41.22
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IMNN 36.86
- SNTI 33.68
- Support Level
- IMNN $5.53
- SNTI $1.38
- Resistance Level
- IMNN $5.89
- SNTI $1.39
- Average True Range (ATR)
- IMNN 0.32
- SNTI 0.08
- MACD
- IMNN 0.07
- SNTI 0.00
- Stochastic Oscillator
- IMNN 23.81
- SNTI 22.50
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.